Skip Navigation


Human Molecular Genetics Advance Access originally published online on December 21, 2006
Human Molecular Genetics 2007 16(3):295-306; doi:10.1093/hmg/ddl463
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
16/3/295    most recent
ddl463v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Sundar, P. D.
Right arrow Articles by Schellenberg, G. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sundar, P. D.
Right arrow Articles by Schellenberg, G. D.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2006

Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia

Purnima Desai Sundar1,5, Chang-En Yu1,5, Weiva Sieh2, Ellen Steinbart1,5, Ralph M. Garruto6, Kiyomitsu Oyanagi7, Ulla-Katrina Craig8, Thomas D. Bird4,5, Ellen M. Wijsman2,3, Douglas R. Galasko9 and Gerard D. Schellenberg1,4,5,*

1 Department of Medicine, Division of Gerontology and Geriatric Medicine, 2 Department of Medicine, Division of Medical Genetics, 3 Department of Biostatistics, 4 Department of Neurology and Pharmacology, University of Washington, Seattle, WA 98195, USA, 5 Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle Division, Seattle, WA 98108, USA, 6 Department of Anthropology, Laboratory of Biomedical Anthropology and Neurosciences, Binghamton University, SUNY-Binghamton, NY 13902-6000, USA, 7 Department of Neuropathology, Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan, 8 University of Guam, Mangilao, Guam 96923, USA and 9 Department of Neurosciences, University of California, San Diego, La Jolla CA 92093-0662, USA

* To whom correspondence should be addressed at: GRECC S-182B, Veterans Affairs Puget Sound Health Care System, 1660 S. Columbian Way, Seattle, WA 98108, USA. Tel: +1 2067642701; Fax: +1 2067642569; Email: zachdad{at}u.washington.edu

Received October 7, 2006; Accepted December 6, 2006

Unusual forms of amyotrophic lateral sclerosis (ALS-G), Parkinsonism dementia complex (PDC-G) and Guam dementia (GD) are found in Chamorros, the indigenous people of Guam. Neurofibrillary tangles composed of hyperphosphorylated tau are a neuropathologic feature of these closely related disorders. To determine if variation in the gene that encodes microtubule-associated protein tau gene (MAPT) contributes to risk for these disorders, we genotyped nine single nucleotide polymorphism (SNP) sites and one insertion/deletion in the 5' end of MAPT in 54 ALS-G, 135 PDC-G, 153 GD and 258 control subjects, all of whom are Chamorros. Variation at three SNPs (sites 2, 6 and 9) influenced risk for ALS-G, PDC-G and GD. SNP2 acts through a dominant mechanism and is independent of the risk conferred by SNPs 6 and 9, the latter two acting by a recessive mechanism. Persons with the high-risk SNP6 and SNP9 AC/AC diplotype had an increased risk of 3-fold [95% confidence interval (CI)=1.10–8.25] for GD, 4-fold (95% CI=1.40–11.64) for PDC-G and 6-fold (95% CI=1.44–32.14) for ALS-G, compared to persons with other diplotypes after adjusting for SNP2. Carriers of the SNP2 G allele had an increased risk of 1.6-fold (95% CI=1.00–2.62) for GD, 2-fold (95% CI=1.28–3.66) for PDC-G, and 1.5-fold (95% CI=0.74–3.00) for ALS-G, compared to non-carriers after adjusting for SNPs 6 and 9. Others have shown that SNP6 is also associated with risk for progressive supranuclear palsy. These two independent cis-acting sites presumably influence risk for Guam neuro-degenerative disorders by regulating MAPT expression.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
NeurologyHome page
J. C. Steele and P. L. McGeer
The ALS/PDC syndrome of Guam and the cycad hypothesis
Neurology, May 20, 2008; 70(21): 1984 - 1990.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
W. Yang, R. L. Woltjer, I. Sokal, C. Pan, Y. Wang, M. Brodey, E. R. Peskind, J. B. Leverenz, J. Zhang, D. P. Perl, et al.
Quantitative Proteomics Identifies Surfactant-Resistant {alpha}-Synuclein in Cerebral Cortex of Parkinsonism-Dementia Complex of Guam but Not Alzheimer's Disease or Progressive Supranuclear Palsy
Am. J. Pathol., September 1, 2007; 171(3): 993 - 1002.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
D. R. Williams, J. L. Holton, C. Strand, A. Pittman, R. de Silva, A. J. Lees, and T. Revesz
Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome
Brain, June 1, 2007; 130(6): 1566 - 1576.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
R. P. Friedland and C. Armon
Tales of Pacific tangles: Cycad exposure and Guamanian neurodegenerative diseases
Neurology, May 22, 2007; 68(21): 1759 - 1761.
[Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.